ストックスクリーナーアプリを入手
10.89
1.24%
-0.16
前日終値:
$11.05
開ける：
$11
24時間の取引高:
1.63M
Relative Volume:
0.49
時価総額：
$2.83B
収益：
$6.41B
当期純損益:
$1.30B
株価収益率:
2.1607
EPS:
5.04
ネットキャッシュフロー:
$646.00M
1週間 パフォーマンス:
-13.66%
1か月 パフォーマンス:
-28.72%
6か月 パフォーマンス:
-39.17%
1年 パフォーマンス:
-38.66%
1日の値動き範囲:
$10.87
$11.21
1週間の範囲:
$10.87
$12.42
52週間の値動き範囲:
$10.87
$23.10
Organon Co Stock (OGN) Company Profile
OGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
10.89 | 2.83B | 6.41B | 1.30B | 646.00M | 5.04 |
|
LLY
Lilly Eli Co
|
737.56 | 667.64B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
154.13 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
171.13 | 308.39B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
63.33 | 281.01B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.70 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Organon Co Stock (OGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-06 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-11-03 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-21 | 開始されました | Barclays | Overweight |
| 2023-03-16 | 開始されました | Raymond James | Outperform |
| 2022-10-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 開始されました | Piper Sandler | Neutral |
| 2021-09-01 | 開始されました | BofA Securities | Buy |
| 2021-07-22 | 開始されました | Citigroup | Buy |
| 2021-06-15 | 開始されました | JP Morgan | Neutral |
| 2021-06-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Organon Co (OGN) 最新ニュース
Ganirelix Market Is Booming Worldwide 2025-2032 | Organon & Co.,Merck & Co., Inc.,Ferring Pharmaceuticals - openPR.com
Organon stock hits 52-week low at $10.92 amid market challenges - Investing.com Australia
Organon expands board with new director from Takeda - Investing.com
Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Bluefield Daily Telegraph
Takeda President Ramona Sequeira Joins Organon Board: Major Win for Women's Health Giant - Stock Titan
Organon & CoExpects $6 Million Milestone Expense In Q1 2025 - MarketScreener
Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Bluefield Daily Telegraph
Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan
Organon (OGN) Laps the Stock Market: Here's Why - Yahoo Finance
EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - MarketScreener
Organon's NDURVA Cream Gets Health Canada Approval for Plaque Psoriasis Treatment - MarketScreener
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance
European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - 뉴스와이어
Organon's Ba2 CFR affirmed by Moody's, outlook revised to negative - Investing.com Australia
Organon’s Ba2 CFR affirmed by Moody’s, outlook revised to negative - Investing.com Canada
Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength? - Nasdaq
Organon (OGN) Sees Flat Revenue, Downgraded Full-Year Outlook - GuruFocus
Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance
Organon Enters Oversold Territory - Nasdaq
Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune
Organon stock hits 52-week low at $13.84 amid market challenges - Investing.com Canada
Organon stock hits 52-week low at $13.84 amid market challenges By Investing.com - Investing.com South Africa
Organon (OGN) Stock Moves -1.83%: What You Should Know - Yahoo Finance
Why Organon (OGN) Could Beat Earnings Estimates Again - Yahoo Finance
Organon acquires Actemra biosimilar’s US rights from Biogen - Pharmaceutical Technology
Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition - insights.citeline.com
Organon acquires US rights to arthritis biosimilar TOFIDENCE By Investing.com - Investing.com South Africa
Organon Expands Biosimilar Portfolio With Tofidence Acquisition - Managed Healthcare Executive
Organon Acquires TOFIDENCE - citybiz
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance
Organon Acquires Tofidence for Intravenous Infusion in US - MarketScreener
Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra - Seeking Alpha
Organon acquires rights for Tofidence from Biogen - TipRanks
Organon acquires US rights to arthritis biosimilar TOFIDENCE - Investing.com
Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. - Bluefield Daily Telegraph
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal - Stock Titan
Natixis Advisors LLC Decreases Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat
Organon (OGN) Stock Moves -0.34%: What You Should Know - Yahoo Finance
Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug - MarketScreener
European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11 - MarketScreener
Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11 - TipRanks
Major Win: Organon's Breast Cancer Drug Gets Critical EMA Validation After Trial Success - Stock Titan
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance
Organon & Co. (OGN): A Deep Value Play with a 35.96% Upside Potential and an Attractive 7.61% Dividend Yield - DirectorsTalk Interviews
Connor Clark & Lunn Investment Management Ltd. Purchases New Position in Organon & Co. (NYSE:OGN) - MarketBeat
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price - simplywall.st
Organon announces departure of chief commercial officer - MSN
(OGN) Technical Data - Stock Traders Daily
Organon (OGN) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Organon Co (OGN) 財務データ
収益
当期純利益
現金流量
EPS
Organon Co (OGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Karp Daniel | Executive VP, Corp. Dev. |
Mar 31 '25 |
Option Exercise |
0.00 |
34,677 |
0 |
44,515 |
| Stahler Rachel A | Chief Information Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
18,334 |
0 |
78,994 |
| WALSH MATTHEW M | Chief Financial Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
34,870 |
0 |
136,903 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Mar 31 '25 |
Option Exercise |
0.00 |
8,865 |
0 |
20,552 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
Mar 31 '25 |
Option Exercise |
0.00 |
21,376 |
0 |
45,668 |
| DiMarco Kathryn | Corporate Controller |
Mar 31 '25 |
Option Exercise |
0.00 |
23,435 |
0 |
40,211 |
| Nisita Vittorio | Head of Global Business Svcs |
Mar 31 '25 |
Option Exercise |
0.00 |
13,231 |
0 |
44,803 |
| Morrissey Joseph T. Jr. | Head of Manufacturing |
Mar 31 '25 |
Option Exercise |
0.00 |
21,483 |
0 |
73,275 |
| Ali Kevin | Chief Executive Officer |
Mar 31 '25 |
Option Exercise |
0.00 |
109,204 |
0 |
260,687 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Nov 07 '24 |
Option Exercise |
0.00 |
6,446 |
0 |
13,987 |
1.64%
0.37%
大文字化:
|
ボリューム (24 時間):